In Situ Evaluation of Anticancer Monoclonal Antibody Nivolumab-DNA Interaction Using a DNA-Electrochemical Biosensor

摘要

The cancer treatment based on monoclonal antibodies has become one of the most successful therapeutic strategies. Among the monoclonal antibodies, nivolumab (NIVO) stands out as being a relatively new anticancer drug. The NIVO-dsDNA interaction was evaluated, in incubated solutions, by differential pulse voltammetry, UV-Visible spectrophotometry and gel electrophoresis, and in situ with dsDNA-, poly[G]- or poly[A]-electrochemical biosensors, by differential pulse voltammetry, electrochemical impedance spectroscopy, and quartz crystal microbalance. The interfacial behaviour of the dsDNA-electrochemical biosensor was also investigated by cyclic voltammetry and electrochemical impedance spectroscopy. The NIVO-dsDNA interaction mechanism caused, for shorter times, the binding of the NIVO to DNA, resulting in a NIVO-dsDNA complex, and for longer times, the relaxation/unwinding of this complex structure. The monoclonal antibody NIVO did not promote oxidative damage to DNA.